86 results match your criteria: "Mass General Institute for Neurodegenerative Disease[Affiliation]"

Exosomes can serve as delivery vehicles for advanced therapeutics. The components necessary and sufficient to support exosomal delivery have not been established. Here we connect biochemical composition and activity of exosomes to optimize exosome-mediated delivery of small interfering RNAs (siRNAs).

View Article and Find Full Text PDF
Article Synopsis
  • * Mesenchymal stem cells (MSCs), especially those from umbilical cords, are identified as optimal for producing exosomes, but methods for large-scale production have been limited.
  • * Researchers developed scalable cultivation techniques using 3D cultures and filtration processes, significantly increasing exosome yield and potency, paving the way for practical clinical applications.
View Article and Find Full Text PDF

The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer's disease.

J Neuroinflammation

September 2018

Alzheimer's Disease Research Laboratory, Department of Neurology, Mass General Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, 114 16th Street, Charlestown, MA, 02129, USA.

Background: Misfolding of microtubule-associated protein tau (MAPT) within neurons into neurofibrillary tangles is an important pathological feature of Alzheimer's disease (AD). Tau pathology correlates with cognitive decline in AD and follows a stereotypical anatomical course; several recent studies indicate that tau pathology spreads inter-neuronally via misfolded tau "seeds." Previous research has focused on neurons as the source of these tau seeds.

View Article and Find Full Text PDF

Effective transvascular delivery of therapeutic oligonucleotides to the brain presents a major hurdle to the development of gene silencing technologies for treatment of genetically defined neurological disorders. Distribution to the brain after systemic administrations is hampered by the low permeability of the blood-brain barrier (BBB) and the rapid clearance kinetics of these drugs from the blood. Here we show that transient osmotic disruption of the BBB enables transvascular delivery of hydrophobically modified small interfering RNA (hsiRNA) to the rat brain.

View Article and Find Full Text PDF

Background: Several non-motor features may individually contribute to identify prodromal Parkinson's disease (PD), but little is known on how they interact.

Methods: We conducted a case-control study nested within the Health Professionals Follow-up Study in a large cohort of men age 40-75 at recruitment in 1986. Cases (n=120) had confirmed PD, were<85 in January 2012, returned a 2012 questionnaire with questions on probable rapid eye movement sleep behaviour disorder (RBD) and constipation sent to all cohort participants and completed in 2014 the Brief Smell Identification Test and a questionnaire assessing parkinsonism and other non-motor PD features (including depressive symptoms, excessive daytime sleepiness, impaired colour vision and body pain).

View Article and Find Full Text PDF

Models for predicting risk of dementia: a systematic review.

J Neurol Neurosurg Psychiatry

April 2019

Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China

Background: Information from well-established dementia risk models can guide targeted intervention to prevent dementia, in addition to the main purpose of quantifying the probability of developing dementia in the future.

Methods: We conducted a systematic review of published studies on existing dementia risk models. The models were assessed by sensitivity, specificity and area under the curve (AUC) from receiver operating characteristic analysis.

View Article and Find Full Text PDF

Extracellular vesicles are promising delivery vesicles for therapeutic RNAs. Small interfering RNA (siRNA) conjugation to cholesterol enables efficient and reproducible loading of extracellular vesicles with the therapeutic cargo. siRNAs are typically chemically modified to fit an application.

View Article and Find Full Text PDF

Calsenilin modulates A-type potassium channels, regulates presenilin-mediated γ-secretase activity, and represses prodynorphin and genes expression. RhoA is involved in various cellular functions including proliferation, differentiation, migration, transcription, and regulation of the actin cytoskeleton. Although recent studies demonstrate that calsenilin can directly interact with RhoA and that RhoA inactivation is essential for neuritogenesis, it is uncertain whether there is a link between calsenilin and RhoA-regulated neuritogenesis.

View Article and Find Full Text PDF
Article Synopsis
  • * The new amide-modified, phosphocholine-containing DHA-hsiRNA (PC-DHA-hsiRNA) was created to potentially improve delivery and silencing of Huntingtin (Htt) mRNA in mouse brain cells.
  • * While PC-DHA-hsiRNA effectively silences Htt mRNA and protein, its performance isn't significantly better than the original DHA-hsiRNA, and high doses may cause reactive astrogliosis, highlighting the complexity in creating safe and effective CNS delivery systems. *
View Article and Find Full Text PDF

Several studies have been conducted with mixed results since our initial report of increased Parkinson's disease risk in individuals with red hair and/or red hair-associated p.R151C variant of the gene, both of which confer high melanoma risk. We performed a meta-analysis of six publications on red hair, , and Parkinson's disease.

View Article and Find Full Text PDF

Corrigendum to "Fragile X syndrome: Are signaling lipids the missing culprits?" [Biochimie 130C (2016) 188-194].

Biochimie

April 2017

Institut de Génétique et de Biologie Moléculaire et Cellulaire, 67404 Illkirch, France; Centre National de la Recherche Scientifique, UMR7104, 67404 Illkirch, France; Institut National de la Santé et de la Recherche Médicale, U964, 67404 Illkirch, France; Université de Strasbourg, 67084, Strasbourg, France. Electronic address:

View Article and Find Full Text PDF

A given cell makes exchanges with its neighbors through a variety of means ranging from diffusible factors to vesicles. Cells use also tunneling nanotubes (TNTs), filamentous-actin-containing membranous structures that bridge and connect cells. First described in immune cells, TNTs facilitate HIV-1 transfer and are found in various cell types, including neurons.

View Article and Find Full Text PDF

Fragile X syndrome: Are signaling lipids the missing culprits?

Biochimie

November 2016

Institut de Génétique et de Biologie Moléculaire et Cellulaire, 67404 Illkirch, France; Centre National de la Recherche Scientifique, UMR7104, 67404 Illkirch, France; Institut National de la Santé et de la Recherche Médicale, U964, 67404 Illkirch, France; Université de Strasbourg, 67084 Strasbourg, France. Electronic address:

Fragile X syndrome (FXS) is the most common cause of inherited intellectual disability and autism. FXS results from the absence of FMRP, an RNA binding protein associated to ribosomes that influences the translation of specific mRNAs in post-synaptic compartments of neurons. The main molecular consequence of the absence of FMRP is an excessive translation of neuronal protein in several areas of the brain.

View Article and Find Full Text PDF

We introduce a new class of fractal reaction kinetics wherein two or more distinct fractal structures are synthesized as parts of a singular cascade reaction in a single chemical beaker. Two examples: sphere ↔ spiral & triangle ↔ square fractals, grow 10(6) orders from a single dendrimer (8 nm) to the visible scale.

View Article and Find Full Text PDF

The progression of many neurodegenerative diseases is assumed to be caused by misfolding of specific characteristic diseases related proteins, resulting in aggregation and fibril formation of these proteins. Protein misfolding associated age related diseases, although different in disease manifestations, share striking similarities. In all cases, one disease protein aggregates and loses its function or additionally shows a toxic gain of function.

View Article and Find Full Text PDF

Background: Silencing mutant huntingtin mRNA by RNA interference (RNAi) is a therapeutic strategy for Huntington's disease. RNAi induces specific endonucleolytic cleavage of the target HTT mRNA, followed by exonucleolytic processing of the cleaved mRNA fragments.

Objectives: We investigated the clearance of huntingtin mRNA cleavage products following RNAi, to find if particular huntingtin mRNA sequences persist.

View Article and Find Full Text PDF

Applications of RNA interference for neuroscience research have been limited by a lack of simple and efficient methods to deliver oligonucleotides to primary neurons in culture and to the brain. Here, we show that primary neurons rapidly internalize hydrophobically modified siRNAs (hsiRNAs) added directly to the culture medium without lipid formulation. We identify functional hsiRNAs targeting the mRNA of huntingtin, the mutation of which is responsible for Huntington's disease, and show that direct uptake in neurons induces potent and specific silencing in vitro.

View Article and Find Full Text PDF

Alzheimer's disease (AD) therapeutics based on the amyloid hypothesis have shown minimal efficacy in patients, suggesting that the activity of amyloid beta (Aβ) represents only one aspect of AD pathogenesis. Since neuroinflammation is thought to play an important role in AD, we hypothesized that cytokines may play a direct role in promoting neuronal death. Here, we profiled cytokine expression in a small cohort of human AD and control brain tissues.

View Article and Find Full Text PDF

TR-FRET Assays for Endogenous Huntingtin Protein Level in Mouse Cells.

J Huntingtons Dis

February 2016

State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China Mass General Institute for Neurodegenerative Disease, Charlestown, MA, USA.

High-throughput measurement of huntingtin (Htt) levels is useful for Huntington's disease research. For example, identification of genetic or chemical modifiers that reduce Htt levels by high-throughput screening provides promising strategy for HD drug discovery. In the human cells, high-throughput measurement of Htt levels has been established based on the Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET) technology, using the 2B7/MW1 antibody pair.

View Article and Find Full Text PDF

Tracking the earliest pathologic changes in Alzheimer disease.

Neurology

May 2014

From the Helen Wills Neuroscience Institute (S.M.L.), University of California and Lawrence Berkeley National Laboratory; and the Mass General Institute for Neurodegenerative Disease and C. S. Kubik Laboratory for Neuropathology (M.P.F.), Massachusetts General Hospital, Harvard Medical School, Charlestown.

A current challenge in Alzheimer disease (AD) research is to identify the sequence of pathologic changes that occurs during preclinical stages of disease in advance of cognitive decline. The timing of appearance of the 2 pathologic hallmarks of AD-amyloid deposition and tau-mediated neurodegeneration-is a particular topic of debate, with researchers drawing on a broad range of genetic, neuroimaging, fluid biomarker, animal, and autopsy studies to piece together the series of events ultimately leading to the plaques, neurofibrillary tangles, and cognitive deficits that define AD.

View Article and Find Full Text PDF

Drugging unconventional targets: insights from Huntington's disease.

Trends Pharmacol Sci

February 2014

State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Mass General Institute for Neurodegenerative Disease, Charlestown, MA, USA. Electronic address:

Classical targeted drug discovery is based on targeting druggable targets, typically kinases and receptors of which the function can be agonized or antagonized. This strategy meets difficulties in cases such as Huntington's disease (HD) and similar neurodegenerative disorders, where the pathological function of the protein causing the disease is not clear. HD is caused by mutant HTT protein (mHTT) containing an expanded polyglutamine (polyQ) stretch, but the function of mHTT and how mHTT causes HD are unknown, thus preventing efforts to screen for mHTT 'inhibitors'.

View Article and Find Full Text PDF

Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease.

J Neuropathol Exp Neurol

June 2013

Mass General Institute for Neurodegenerative Disease, Massachusetts General Hospital, Massachusetts Alzheimer Disease Research Center, and Harvard Medical School, Charlestown, Massachusetts, USA.

Although it is clear that astrocytes and microglia cluster around dense-core amyloid plaques in Alzheimer disease (AD), whether they are primarily attracted to amyloid deposits or are just reacting to plaque-associated neuritic damage remains elusive. We postulate that astrocytes and microglia may differentially respond to fibrillar amyloid β. Therefore, we quantified the size distribution of dense-core thioflavin-S (ThioS)-positive plaques in the temporal neocortex of 40 AD patients and the microglial and astrocyte responses in their vicinity (≤50 μm) and performed correlations between both measures.

View Article and Find Full Text PDF

Genome-wide increase in histone H2A ubiquitylation in a mouse model of Huntington's disease.

J Huntingtons Dis

September 2014

Department of Neurology, Mass General Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, MA, USA.

Background: Huntington's disease (HD) is a neurodegenerative disorder with selective vulnerability of striatal neurons and involves extensive transcriptional dysregulation early in the disease process. Previous work in cell and mouse models has shown that histone modifications are altered in HD. Specifically, monoubiquitylated histone H2A (uH2A) is present at the promoters of downregulated genes which led to the hypothesis that uH2A plays a role in transcriptional silencing in HD.

View Article and Find Full Text PDF

Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein.

J Neurosci

October 2011

Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.

Increased intracellular levels of α-synuclein are implicated in Parkinson's disease and related disorders and may be caused by alterations in the ubiquitin-proteasome system (UPS) or the autophagy-lysosomal pathway (ALP). A critical question remains how α-synuclein is degraded by neurons in vivo. To address this, our study uses α-synuclein transgenic mice, expressing human α-synuclein or α-synuclein-eGFP under the (h)PDGF-β promoter, in combination with in vivo pharmacologic and multiphoton imaging strategies to systematically test degradation pathways in the living mouse brain.

View Article and Find Full Text PDF

Genetic Parkinson disease (PD) has been associated with mutations in PINK1, a gene encoding a mitochondrial kinase implicated in the regulation of mitochondrial degradation. While the studies so far examined PINK1 function in non-neuronal systems or through PINK1 knockdown approaches, there is an imperative to examine the role of endogenous PINK1 in appropriate human-derived and biologically relevant cell models. Here we report the generation of induced pluripotent stem (iPS) cells from skin fibroblasts taken from three PD patients with nonsense (c.

View Article and Find Full Text PDF